Search Results - "Spitzer, Gary"

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat by Oppliger Leibundgut, Elisabeth, Haubitz, Monika, Burington, Bart, Ottmann, Oliver G, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A, Röth, Alexander, Snyder, David S, Baerlocher, Gabriela M

“…In a phase-2 study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory…”
Get full text

High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry by Berry, D. A.

Get full text

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression by Jacobsen, Eric D., Sharman, Jeff P., Oki, Yasuhiro, Advani, Ranjana H., Winter, Jane N., Bello, Celeste M., Spitzer, Gary, Palanca-Wessels, Maria Corinna, Kennedy, Dana A., Levine, Pamela, Yang, Jing, Bartlett, Nancy L.

“…Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), variably express CD30. This phase 2, open-label study evaluated…”
Get full text

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia by Baerlocher, Gabriela M, Oppliger Leibundgut, Elisabeth, Ottmann, Oliver G, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A, Röth, Alexander, Daskalakis, Michael, Burington, Bart, Stuart, Monic, Snyder, David S

“…In an open-label, phase 2 study, all 18 patients who received the telomerase inhibitor imetelstat had a response; 16 responses were complete. Patients received…”
Get full text

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma by Benson, Jr, Don M, Cohen, Adam D, Jagannath, Sundar, Munshi, Nikhil C, Spitzer, Gary, Hofmeister, Craig C, Efebera, Yvonne A, Andre, Pascale, Zerbib, Robert, Caligiuri, Michael A

“…Natural killer (NK) cells may play an important role in the immune response to multiple myeloma; however, multiple myeloma cells express killer…”
Get full text

Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians by Anderson, Karl E., Lobo, Raynah, Salazar, Denise, Schloetter, Mary, Spitzer, Gary, White, Amy L., Young, Randolph M., Bonkovsky, Herbert L., Frank, Elizabeth L., Mora, Jordanna, Tortorelli, Silvia

“…Acute hepatic porphyria (AHP) is a group of rare, metabolic diseases where patients can experience acute neurovisceral attacks, chronic symptoms, and long-term…”
Get full text

Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer by Spitzer, Gary, Socinski, Mark A

Get full text

Clinical Utility of a Blood-based Protein Assay on Diagnostic Colonoscopy Referrals for Elevated-risk Colorectal Cancer Patients in Primary Care by Peabody, John, Rahim, Arshad, Wilcox, Bruce, McGehee, Carrie, Estigarribia, Erwin, Paculdo, David, Arzadon, Aislinn, Fugaro, Steven, Tran, Mary, Spitzer, Gary

“…Colonoscopies are effective in finding early stage colorectal cancer (CRC), which when found in a timely manner, dramatically improve survival rates. A…”
Get full text

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matasar, Matthew J., Czuczman, Myron S., Rodriguez, Maria Alma, Fennessy, Michael, Shea, Thomas C., Spitzer, Gary, Lossos, Izidore S., Kharfan-Dabaja, Mohamed A., Joyce, Robin, Fayad, Luis, Henkel, Kristen, Liao, Qiming, Edvardsen, Klaus, Jewell, Roxanne C., Fecteau, Doug, Singh, Rajendra P., Lisby, Steen, Moskowitz, Craig H.

“…Standard treatment of transplant-eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL) consists of rituximab and platinum-based chemotherapy,…”
Get full text

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study by Raza, Azra, Al-Kali, Aref, Tibes, Raoul, Spitzer, Gary, Gaddh, Manila, Tycko, Benjamin, Lee, Sangmin, Galili, Naomi, Ali, Abdullah Mahmood, Mears, John G., Mukherjee, Siddhartha, Shelton, Ryan, Fruchtman, Steven M., Petrone, Michael E., Zbyszewski, Patrick S., Heaney, Mark Lawrence

“…Background: LR-MDS patients have limited treatment options and a large number are transfusion dependent (Raza A, Expert Opinion 2016, 4:9). Erythropoiesis…”
Get full text

Dynamics of Mutations in Patients with ET Treated with Imetelstat by Oppliger Leibundgut, Elisabeth, Haubitz, Monika, Burington, Bart, Ottmann, Oliver G., Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A, Roeth, Alexander, Snyder, David S., Baerlocher, Gabriela M.

“…Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (ET)…”
Get full text

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia by Haubitz, Monika, Oppliger Leibundgut, Elisabeth, Helsen, Ingrid, Hiltbrunner, Dania, Burington, Bart, Ottmann, Oliver G., Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A, Röth, Alexander, Snyder, David S., Baerlocher, Gabriela M.

“…Background/Aims: Myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF), are clonal…”
Get full text

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses by Raza, Azra, Tycko, Benjamin, Lee, Sangmin, Galili, Naomi, Ali, Abdullah, Eisenberger, Andrew, Mears, John G., Al-Kali, Aref, Tibes, Raoul, Spitzer, Gary, Wilhelm, Francois, Mukherjee, Siddhartha

“…▪ Rigosertib, a novel orally bioavailable small molecule inhibitor of PI3-Kinase and PLK1 pathways, was tested in a phase II study in lower risk…”
Get full text

A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma by Benson, Don M., Cohen, Adam D, Hofmeister, Craig C, Nikhil, Munshi C, Jagannath, Sundar, Efebera, Yvonne A, Spitzer, Gary, Zerbib, Robert, Andre, Pascale, Oxier, Shawna, Caligiuri, Michael A.

“…Multiple myeloma (MM) remains an essentially incurable plasma cell malignancy. MM utilizes specific immunoevasive strategies to avoid natural killer (NK) cell…”
Get full text

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results by Benson, Don M., Cohen, Adam D, Munshi, Nikhil C., Jagannath, Sundar, Spitzer, Gary, Hofmeister, Craig C., Zerbib, Robert, Andre, Pascale, Efebera, Yvonne A, Oxier, Shawna, Caligiuri, Michael A.

“…Abstract 4058 Multiple myeloma (MM) cells upregulate MHC class I antigens which serve as ligands to inhibitory Killer Immunoglobulin-like Receptors (KIR) as a…”
Get full text

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results by Baerlocher, Gabriela M., Leibundgut, Elisabeth Oppliger, Ayran, Christina, Blaney, Martha, Burington, Bart, Morfeld, Dianne, Odenike, Olatoyosi, Ottman, Oliver, Reddy, Anita, Roeth, Alexander, Spitzer, Gary, Stuart, Monic J., Verstovsek, Srdan, Snyder, David S.

“…Abstract 179 Myeloproliferative neoplasms (MPNs), such as essential thrombocythemia (ET), are driven by neoplastic progenitor cells. The JAK2 V617F mutation…”
Get full text

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT) by Matasar, Matthew J., Czuczman, Myron S., Rodriguez, Maria Alma, Fennessy, Michael, Shea, Thomas C., Spitzer, Gary, Lossos, Izidore S, Kharfan-Dabaja, Mohamed A., Joyce, Robin, Fayad, Luis, Liao, Qiming, Edvardsen, Klaus, Lisby, Steen, Moskowitz, Craig H.

“…Abstract 957 For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), standard-of-care second-line therapy in patients eligible for…”
Get full text

Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer by Umsawasdi, T, Valdivieso, M, Chen, T T, Barkley, Jr, H T, Booser, D J, Chiuten, D F, Dhingra, H M, Murphy, W K, Dixon, C L, Farha, P

“…We have studied the clinical impact of elective brain irradiation (EBI) in patients with locally advanced, non-small cell lung cancer (LA-NSC). All patients…”
Get full text

Plasma cell disorders: myeloma and related conditions. Diagnosis and management by Spitzer, Gary

Get more information

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response by Rifkin, Robert M., Spitzer, Gary, Greenspan, Andrew, Schwerkoske, John F., Mandanas, Romeo A., Stephenson, Joe, Kannarkat, George T., Zhan, Feng, Asmar, Lina, Beveridge, Roy

“…Multiple myeloma (MM) is the second most common hematologic malignancy. Presently, the majority of suitable MM patients who undergo high-dose melphalan therapy…”
Get full text